NEW FUNDING OPPORTUNITIES:
AACR-Aflac Incorporated Career Development Award for Pediatric Cancer Research
Sponsor: AACR, Aflac, Inc.
Deadline: App 11/12/2012
Encouragement and support for junior faculty who are in the first five years of a faculty appointment (at the start of the grant term) to conduct pediatric cancer research and establish successful career paths in this field. The research proposed for funding may be basic, translational, clinical or epidemiological in nature and must have direct applicability and relevance to pediatric cancer.
AACR – National Brain Tumor Society Career Development Award for Translational Brain Tumor Research
Sponsor: AACR, National Brain Tumor Society
Deadline: App 11/12/2012
Encouragement and support for junior faculty who are in the first five years of a faculty appointment (at the start of the grant term) to conduct brain tumor research and establish successful career paths in this field. The research proposed for funding must be translational in nature and have direct applicability and relevance to brain tumors.
AACR Dharma Master Jiantai Innovative Grant for Lung Cancer Research
Sponsor: AACR, Dharma Master Jiantai
Deadline: App 11/20/2012
Funding granted to an investigator for an existing project that develops and studies new ideas and approaches that have direct application and relevance to lung cancer. Following the Grant-in-Aid of Research model, this support supplements existing funding for an investigator conducting a basic or translational research project that will contribute to the acceleration of progress against lung cancer, for the ultimate goal of improving patient care.
Advanced Development of Informatics Technology (U24)
Sponsor: NIH, NCI
Deadline: Earliest submission – 1/22/2013
Purpose is to invite Cooperative Agreement (U24) applications for advanced development and enhancement of emerging informatics technologies to improve the acquisition, management, analysis, and dissemination of data and knowledge in cancer research. An emerging informatics technology is defined as one that has passed the initial prototyping and pilot development stage, has demonstrated potential to have a significant and broader impact, has compelling reasons for further improvement and enhancement, and has not been widely adopted in the cancer research field. If successful, these technologies would accelerate research in cancer biology, cancer treatment and diagnosis, cancer prevention, cancer control and epidemiology, and/or cancer health disparities. This FOA is one component of the NCI's Informatics Technology for Cancer Research (ITCR) Initiative whose central mission is to promote research-driven informatics technology development. Potential applicants who are interested in early-stage development should consult companion FOAs listed on the previous page. Applications that focus on informatics data processing and analysis or mathematical/statistical modeling alone without informatics technology development are not appropriate for this FOA.
Early-Stage Development of Informatics Technology (U01)
Sponsors: NIH, NCI
Deadline: Earliest submission 12/22/2012
Purpose is to invite Cooperative Agreement (U01) applications for the development of enabling informatics technologies to improve the acquisition, management, analysis, and dissemination of data and knowledge in cancer research. As a component of the NCI's Informatics Technology for Cancer Research (ITCR) Initiative, this FOA focuses on early-stage development from prototyping to hardening and adaptation. The central mission of the ITCR is to promote research-driven informatics technology development. In order to be successful, proposed development plans must have a clear rationale on why the proposed technology is needed and how it will benefit the cancer research community. In addition, mechanisms to solicit feedback from users and collaborators throughout the development process should be included. Applications that focus on data processing and analysis or mathematical/statistical modeling alone without new technology development are not appropriate for this FOA.
Exploratory/Developmental Bioengineering Research Grants (EBRG) (R21)
Sponsors: NIH; NCI; National Institute of Biomedical Imaging and Bioengineering; National Heart, Lung and Blood Institute; National Institute on Alcohol Abuse and Alcoholism; National Institute of Arthritis and Musculoskeletal and Skin Diseases; Eunice Kennedy Shriver National Institute of Child Health and Human Development; National Institute of Dental and Craniofacial Research; National Institute on Drug Abuse; National Institute of Environmental Health Sciences; National Institute of Neurological Disorders and Stroke; Office of Research on Women’s Health
Deadline: 1/16/2013
Purpose is to establish the feasibility of technologies, techniques or methods that: 1) explore a unique multidisciplinary approach to a biomedical challenge; 2) are high-risk but have a considerable pay-off; and 3) develop data which can lead to significant future research. An EBRG application may propose hypothesis-driven, discovery-driven, developmental, or design-directed research and is appropriate for evaluating unproven approaches for which there is minimal or no preliminary data.
Effects of In Utero Alcohol Exposure on Adult Health and Disease (R01)
Sponsor: NIU, National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Deadline: Earliest submission – 1/5/2013
Intended for support of novel research on how prenatal alcohol exposure may contribute to the tiology of chronic diseases and health conditions later in life. Central to this theme is the developmental origins of health and disease (DOHaD) concept, which suggests that fetal adaptations in response to adverse intrauterine conditions may increase the risk for childhood and adult disease. The foald of this FOA is to stimulate a broad range of research to: 1)leverage existing prospective birth cohorts to define the role fo maternal alcohol consumption in the DOHaD process; 2) investigate the biological, cellular and molecular mechanisms by which prenatal alcohol exposure may impact disease outcomes later in life; and 3) identify biomarkers associated with gestational alcohol exposure that may predict adult disease susceptibility in exposed offspring. Studies supported by this FOA will provide fundamental insights into a possible fetal-basis to adult disease that is influenced by maternal alcohol use.
Effects of In Utero Alcohol Exposure on Adult Health and Disease (R21)
Sponsor: NIU, National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Deadline: Earliest submission – 1/16/2013
Intended for support of novel research on how prenatal alcohol exposure may contribute to the tiology of chronic diseases and health conditions later in life. Central to this theme is the developmental origins of health and disease (DOHaD) concept, which suggests that fetal adaptations in response to adverse intrauterine conditions may increase the risk for childhood and adult disease. The foald of this FOA is to stimulate a broad range of research to: 1)leverage existing prospective birth cohorts to define the role fo maternal alcohol consumption in the DOHaD process; 2) investigate the biological, cellular and molecular mechanisms by which prenatal alcohol exposure may impact disease outcomes later in life; and 3) identify biomarkers associated with gestational alcohol exposure that may predict adult disease susceptibility in exposed offspring. Studies supported by this FOA will provide fundamental insights into a possible fetal-basis to adult disease that is influenced by maternal alcohol use.
Examination of Survivorship Care Planning Efficacy and Impact (R21)
Sponsors: NIH, NCI
Deadline: Earliest submission – 1/5/2013
Purpose is to stimulate research to evaluate the effect of care planning on cancer survivors' health and psychosocial outcomes; self-management of late effects and adherence to cancer screening and health behavior guidelines; utilization of follow-up care; organizational-level factors influencing the implementation of care planning; and associated costs. Specifically, the FOA aims to stimulate research that will: 1) develop and test metrics for evaluating the impact of survivorship care planning; 2) evaluate the impact of survivorship care planning on cancer survivors' morbidity, self-management and adherence to care recommendations, utilization of follow-up care, and on systems outcomes, such as associated costs and impact on organizations implementing care planning; and 3) identify models and processes of care that promote effective survivorship care planning. The ultimate goal of this FOA is to generate a body of science that will inform the development and delivery of interventions and best practices in follow-up care for cancer survivors.
Examination of Survivorship Care Planning Efficacy and Impact (R01)
Sponsors: NIH, NCI
Deadline: Earliest submission – 1/5/2013
Purpose is to stimulate research to evaluate the effect of care planning on cancer survivors' health and psychosocial outcomes; self-management of late effects and adherence to cancer screening and health behavior guidelines; utilization of follow-up care; organizational-level factors influencing the implementation of care planning; and associated costs. Specifically, the FOA aims to stimulate research that will: 1) develop and test metrics for evaluating the impact of survivorship care planning; 2) evaluate the impact of survivorship care planning on cancer survivors' morbidity, self-management and adherence to care recommendations, utilization of follow-up care, and on systems outcomes, such as associated costs and impact on organizations implementing care planning; and 3) identify models and processes of care that promote effective survivorship care planning. The ultimate goal of this FOA is to generate a body of science that will inform the development and delivery of interventions and best practices in follow-up care for cancer survivors.
Landon Foundation – AACR INNOVATOR Award for Cancer Prevention Research
Sponsor: Landon Foundation, AACR
Deadline: App 11/20
The Landon Foundation – AACR INNOVATOR Award for Cancer Prevention Research was established to recognize the outstanding achievement of a junior faculty-level scientist working in the field of cancer prevention, and support his or her novel and innovative research that, if successful, will have strong potential for high impact in the cancer prevention field.
Revisions for Early-Stage Development of Informatics Technology (R01)
Sponsor: NIH, NCI
Deadline: Earliest submission – 12/22/1012
Purpose is to is to encourage revision applications (formerly called "competing revisions") from currently funded NCI R01 and R37 (MERIT) research projects for early-stage development of enabling informatics technologies to improve the acquisition, management, analysis, and dissemination of data and knowledge. As a component of the NCI's Informatics Technology for Cancer Research (ITCR) Initiative, this FOA aims to promote interdisciplinary collaboration in the development of innovative computational methods and informatics approaches that are essential for cancer research on all fronts to accelerate scientific discovery and ultimately translate data into knowledge and clinical practice. Applications that focus on data processing and analysis or mathematical/statistical modeling alone without new technology development are not appropriate for this FOA.
Revisions for Early-Stage Development of Informatics Technology (U01)
Sponsors: NIH, NCI
Deadline: Earlist submission 12/22/2012
Purpose is to invite revisions (formerly called "competing revisions") from currently funded NCI U01 cooperative agreement projects for early-stage development of enabling informatics technologies to improve the acquisition, management, analysis, and dissemination of data and knowledge. As a component of the NCI's Informatics Technology for Cancer Research (ITCR) Initiative, this FOA aims to promote interdisciplinary collaboration in the development of innovative computational methods and informatics approaches that are essential for cancer research on all fronts to accelerate scientific discovery and ultimately translate data into knowledge and clinical practice. Applications that focus on data processing and analysis or mathematical/statistical modeling alone without new technology development are not appropriate for this FOA.
Revisions for Early-Stage Development of Informatics Technology (P01)
Sponsors: NIH, NCI
Deadline: Earliest submission 1/22/2013
Purpose is to invite revisions (formerly called "competing revisions") from currently funded NCI P01 program projects for early-stage development of enabling informatics technologies to improve the acquisition, management, analysis, and dissemination of data and knowledge. As a component of the NCI's Informatics Technology for Cancer Research (ITCR) Initiative, this FOA aims to promote interdisciplinary collaboration in the development of innovative computational methods and informatics approaches that are essential for cancer research on all fronts to accelerate scientific discovery and ultimately translate data into knowledge and clinical practice. Applications that focus on data processing and analysis or mathematical/statistical modeling alone without new technology development are not appropriate for this FOA.
Specialized Programs of Research Excellence (SPORESs) in Human Cancer for Years 2012 and 2014 (P50)
Sponsors: NIH, NCI, National Institute of Dental and Craniofacial Research (NIDCR)
National Institute of Neurological Disorders and Stroke (NINDS)
Deadline: 1/24/2013; 9/3/2014
Program will fund 5-year P50 SPORE grants to support state-of-the-art investigator-initiated translational research that will contribute to improved prevention, early detection, diagnosis, and treatment of an organ-specific cancer (or a related group of cancers). SPOREs are expected not only to conduct a wide spectrum of research activities, but also to contribute significantly to the development of specialized shared resource core facilities (cores), improved research model systems, and collaborative research projects with other institutions. The research supported through this program must be translational in nature and must always be focused upon knowledge of human biology stemming from research using cellular, molecular, structural, biochemical, and/or genetic experimental approaches with the goal of a translational human endpoint within the 5 year term of the grant. In addition, SPOREs must include both a Developmental Research Program for pilot studies and a Career Development Program to foster careers in organ-based translational science.
|
